Lynx1 Capital Management LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001910456

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q2 2024 · 17 positions · Total reported value $276.70M · Top-10 concentration 99.0% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 30.3% · 6 new · 2 cut · 2 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -15.3% · vs SPY -17.4% · Prev Value $865.53M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -5.1% · vs SPY -7.2% · Latest Value $646.09M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q2 2024 13F filing, Lynx1 Capital Management LP disclosed 17 equity positions with a combined reported value of $276.70M. The filing implies a focused portfolio: its ten largest positions account for 99.0% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2024 were MRUS ($71.40M), STOK ($70.05M), GHRS ($46.25M). By sector, the heaviest allocations are Health Care 72.2%, Other 27.8%. Versus the prior quarter, allocation shifted toward Health Care (+14.7pp) and away from Other (-14.7pp).

Versus the prior quarter, Lynx1 Capital Management LP opened 6 new positions, trimmed 2 and fully exited 2, a turnover rate of 30.3% of positions. The portfolio's overlap with the prior quarter was 50% of names.

The largest new positions opened in Q2 2024 were CGEM ($6.58M), ALLO ($5.19M), LBPH ($4.52M).

Of the 2 positions fully exited versus the prior quarter, the largest were ALPN ($89.32M), SLN ($11.38M), AUTL ($8.87M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2024)

  • CGEM CULLINAN THERAPEUTICS INC · $6.58M
  • ALLO ALLOGENE THERAPEUTICS INC · $5.19M
  • LBPH LONGBOARD PHARMACEUTICALS IN · $4.52M
  • KNSA KINIKSA PHARMACEUTICALS INTL · $177.37K
  • KRRO KORRO BIO INC · $128.71K
  • VYNE YARROW BIOSCIENCES INC · $31.90K

Fully Exited (vs previous quarter)

  • ALPN ALPINE IMMUNE SCIENCES INC · prev qtr: $89.32M
  • SLN SILENCE THERAPEUTICS PLC · prev qtr: $11.38M
  • AUTL AUTOLUS THERAPEUTICS LTD · prev qtr: $8.87M
  • KNTE KINNATE BIOPHARMA INC · prev qtr: $5.27M
  • NKTR NEKTAR THERAPEUTICS · prev qtr: $1.93M

Insider Transactions (Form 4)

Latest Lynx1 Capital Management LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-10-26 Buy Korro Bio, Inc. 25,124 $11.75 SEC filing
2026-10-23 Buy Korro Bio, Inc. 2,510 $12.11 SEC filing
2026-10-22 Buy Korro Bio, Inc. 40,000 $11.04 SEC filing
2026-10-22 Buy Korro Bio, Inc. 12,175 $9.68 SEC filing
2026-08-10 Buy Korro Bio, Inc. 1,462 $13.19 SEC filing
2026-08-06 Buy Korro Bio, Inc. 5,222 $11.40 SEC filing
2026-06-25 Buy Passage BIO, Inc. 50,055 $4.12 SEC filing

All insider transactions →

Fund Profile

Lynx1 Capital Management LP, based in Dorado, PR, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q3 2026) lists 31 positions worth $646.09M in total. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).

Firm Snapshot

  • Headquarters: DORADO, PR, United States
  • SEC registration: 801-127585 (status: Approved), registered 2023-04-05
  • Regulatory AUM (Form ADV): $626.68M as of 2026-10-07
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 2 private funds, of which 1 hedge funds

Portfolio Structure

  • 31 positions · $646.09M reported value (Q3 2026)
  • Top 10 holdings = 97.9% of reported value
  • Largest position: GHRS (GH RESEARCH PLC) at 48.2%
  • Average position size: $20.84M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q3 2026: 6 new, 5 added, 2 reduced, 2 exited
  • 18 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 72.2%
Other 27.8%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 1.21M $71.40M 25.80%
25.80%
Reduce
2 5.19M $70.05M 25.32%
25.32%
Add
3 3.97M $46.25M 16.72%
16.72%
Add
4 6.88M $31.79M 11.49%
11.49%
Add
5 5.22M $30.56M 11.05%
11.05%
Hold
6 377.32K $6.58M 2.38%
2.38%
New
7 2.23M $5.19M 1.88%
1.88%
New
8 167.32K $4.52M 1.63%
1.63%
New
9 5.06M $4.02M 1.45%
1.45%
Add
10 492.10K $3.68M 1.33%
1.33%
Reduce
11 600.00K $1.27M 0.46%
0.46%
Hold
12 599.67K $459.95K 0.17%
0.17%
Reduce
13 43.50K $426.76K 0.15%
0.15%
Reduce
14 9.50K $177.37K 0.06%
0.06%
New
15 17.40K $157.12K 0.06%
0.06%
Hold
16 3.80K $128.71K 0.05%
Form 4 · 4 →
0.05%
New
17 16.19K $31.90K 0.01%
0.01%
New

FAQ

What did Lynx1 Capital Management LP buy in 2024-Q2?

In its 2024-Q2 13F filing, Lynx1 Capital Management LP reported 17 equity positions worth $276.70M in aggregate; its largest disclosed positions were MRUS ($71.40M), STOK ($70.05M), GHRS ($46.25M).

How large is Lynx1 Capital Management LP's portfolio?

Lynx1 Capital Management LP reported $276.70M of long equity holdings across 17 positions as of 2024-Q2. Top-10 holdings account for 99.0% of reported value.

What is Lynx1 Capital Management LP's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/lynx1-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →